Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system

Molnupiravir, an urgently approved drug during the Coronavirus Disease 2019 (COVID-19) pandemic, serves as the basis for our study, which relies on the Food and Drug Administration Adverse Event Reporting System (FAERS). The objective is to extract adverse event (AE) signals associated with molnupir...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Yankun, Ma, Lin, Wang, Yuting, Zheng, Jingping, Su, Ling, Lyu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644225/
https://www.ncbi.nlm.nih.gov/pubmed/38026949
http://dx.doi.org/10.3389/fphar.2023.1253799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644225/
https://www.ncbi.nlm.nih.gov/pubmed/38026949
http://dx.doi.org/10.3389/fphar.2023.1253799

Ejemplares similares